Abstract
The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10 , 10 , or 1 μM) decreases nerve growth factor (NGF) secretion measured by enzymelinked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.
Keywords: Gastrin-releasing peptide receptor, RC-3095, nerve growth factor, colon cancer
Protein & Peptide Letters
Title: Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist
Volume: 16 Issue: 6
Author(s): Caroline Brunetto de Farias, Laura Stertz, Rodrigo Cruz Lima, Flavio Kapczinski, Gilberto Schwartsmann and Rafael Roesler
Affiliation:
Keywords: Gastrin-releasing peptide receptor, RC-3095, nerve growth factor, colon cancer
Abstract: The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10 , 10 , or 1 μM) decreases nerve growth factor (NGF) secretion measured by enzymelinked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.
Export Options
About this article
Cite this article as:
de Farias Brunetto Caroline, Stertz Laura, Lima Cruz Rodrigo, Kapczinski Flavio, Schwartsmann Gilberto and Roesler Rafael, Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist, Protein & Peptide Letters 2009; 16 (6) . https://dx.doi.org/10.2174/092986609788490177
DOI https://dx.doi.org/10.2174/092986609788490177 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development
Current Computer-Aided Drug Design Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Letters in Drug Design & Discovery Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry Osteoinductive Small Molecules: Growth Factor Alternatives for Bone Tissue Engineering
Current Pharmaceutical Design Melanocortins As Innovative Drugs for Ischemic Diseases and Neurodegenerative Disorders: Established Data and Perspectives
Current Medicinal Chemistry Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Multiple Means by Which Nitric Oxide can Antagonize Photodynamic Therapy
Current Medicinal Chemistry An Exposition of <sup>11</sup>C and <sup>18</sup>F Radiotracers Synthesis for PET Imaging
Current Radiopharmaceuticals Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Microdialysis: A Technique for Pharmacokinetic-Pharmacodynamic Studies of Oncological Drugs
Current Pharmaceutical Biotechnology Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets